Can tranexamic acid (TXA) injections be used to compound a 10% TXA solution for a patient with melasma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 23, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can TXA Injection Be Used to Compound a 10% TXA Solution?

Yes, tranexamic acid injection formulations can be diluted to create compounded solutions for intradermal use in melasma treatment, with concentrations ranging from 4 mg/mL to 10 mg/mL (1% solution) being most commonly studied and recommended. 1, 2

FDA-Approved Formulation Specifications

The FDA-approved tranexamic acid injection contains 1,000 mg tranexamic acid (100 mg/mL) as a clear, colorless solution in 10 mL single-dose vials. 3 This injectable formulation serves as the base product that can be diluted with saline to achieve lower concentrations suitable for intradermal melasma treatment.

Recommended Concentrations for Melasma Treatment

Evidence-Based Concentration Guidelines

  • The American Academy of Dermatology recommends using a 4% TXA solution (40 mg/mL) prepared by diluting with saline for intradermal microinjections when combining injection technique with microneedling. 1

  • A 10 mg/mL concentration (1% solution) for intradermal injections has demonstrated superior efficacy with 62.7% MASI score reduction compared to 4 mg/mL concentration (39.1% reduction) in head-to-head trials. 2

  • Topical 10% TXA cream (100 mg/mL) produces only fair improvement with 4.2% MASI reduction, making it the least effective delivery method. 2

Critical Distinction: Concentration vs. Route of Administration

The confusion in your question likely stems from mixing concentration percentages with delivery routes. The evidence clearly shows:

  • For intradermal injection: Use 4-10 mg/mL concentrations (0.4%-1% solutions), NOT 10% solutions 1, 2
  • For topical application: 10% concentration (100 mg/mL) can be used but shows minimal efficacy 2
  • A 10% injectable solution would be 100 mg/mL, which is the undiluted FDA formulation and is NOT appropriate for intradermal injection without dilution 3

Practical Compounding Protocol

How to Prepare Appropriate Concentrations

Starting with FDA-approved TXA injection (100 mg/mL): 3

  • For 4 mg/mL solution: Dilute 1 mL of TXA injection with 24 mL normal saline (1:25 dilution)
  • For 10 mg/mL solution: Dilute 1 mL of TXA injection with 9 mL normal saline (1:10 dilution)

Efficacy Hierarchy of TXA Delivery Methods

The American Academy of Dermatology and supporting research establish this clear hierarchy: 1, 4, 5

  1. Intradermal injection (4-10 mg/mL): Most effective
  2. Microneedling with TXA: Comparable efficacy to injection with higher patient satisfaction 6
  3. Oral TXA (250 mg twice daily): Effective but systemic side effects 1, 5
  4. Topical TXA (10%): Least effective 2, 5

Superior Alternative: PRP Combined with Oral TXA

Intradermal PRP injections demonstrate higher efficacy than intradermal TXA injections with similar side effect profiles. 7, 8, 9 The combination of PRP injections with oral TXA 250 mg twice daily achieves 90.48% total efficacy versus 73.68% with TXA alone, with lower disease recurrence rates. 7, 8

Common Pitfall to Avoid

Do not use undiluted 100 mg/mL (10%) TXA injection for intradermal administration. This concentration is designed for intravenous use in bleeding disorders, not dermatologic intradermal injection. 3 The appropriate intradermal concentrations are 25-fold to 10-fold lower (4-10 mg/mL). 1, 2

Treatment Protocol When Using Diluted TXA Injections

  • Administer intradermal injections every 2 weeks for 6 sessions 2, 6
  • Combine with strict sun protection (SPF 50+ reapplied every 2-3 hours) 1, 8
  • Measure treatment response using mMASI scores at baseline, 4 weeks, 8 weeks, and end of treatment 1, 9
  • Consider switching to PRP injections if inadequate response, as PRP shows superior efficacy 7, 8, 9

References

Guideline

Oral Tranexamic Acid Guidelines for Melasma in Adult Women

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Tranexamic Acid for Melasma Treatment: A Split-Face Study.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2020

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment Options for Melasma

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Melasma Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.